Mito-TRFS, the first off-on probe, is used to image the mitochondrial thioredoxin reductase (TrxR2) in live cells[1].
体外研究 (In Vitro)
Mito-TRFS (10 μM) has the maximal absorption at ~375 nm in TE buffer (50 mM Tris-HCl and 1 mM EDTA, pH 7.4) at 37 °C[1]. Mito-TRFS itself has a strong emission at ~480 nm when excited at 375 nm in TE buffer (φ=0.34), but has weak emission when excited at 438 nm[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Immunofluorescence[1].
Cell Line:
HeLa cells.
Concentration:
1 μM.
Incubation Time:
2 h.
Result:
Mito-TRFS is localized predominantly in the mitochondria of live cells.
分子量
820.70
Formula
C38H34IN2O5PS2
CAS 号
1859102-62-7
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Yaping Liu, et al. A small molecule probe reveals declined mitochondrial thioredoxin reductase activity in a Parkinson’s disease model. Chem Commun (Camb). 2016 Feb 7;52(11):2296-9.
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells[1].
体外研究 (In Vitro)
Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 µM and 0.69 µM, respectively[1]. Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 µM and 2.4 µM, respectively in H2030BrM3 cells[1]. Mito-LND (1 µM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells[1]. Mito-LND (2 µM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
Mito-LND (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis[1]. Mito-LND also decreases the rate of growth of A549 tumor xenografts[1]. Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Athymic nude mice (5 weeks) injected with H2030BrM3 cells[1]
Dosage:
7.5 µmol/kg
Administration:
Oral gavage; 5 days per week; for 3 consecutive weeks
Result:
Significantly decreased tumor progression.
分子量
801.62
Formula
C43H45BrCl2N3OP
CAS 号
2361564-49-8
运输条件
Room temperature in continental US; may vary elsewhere.